Grifols strengthens its position among the world’s most sustainable biotechnology companies after improving its Dow Jones Best-in-Class score

Barcelona, Spain, May 4, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, has strengthened its position among the world’s most sustainable biotechnology companies after improving its score in the Dow Jones Best-in-Class indices and marking five and six consecutive years of inclusion in their World and Europe versions, respectively. The company achieved a score of 74 points, four more than the previous year, consolidating its position as one of the global benchmarks in sustainability within the sector.

The company delivered solid performance across the three ESG dimensions (Environmental, Social and Governance). Grifols achieved the highest possible score, 100 points, in key areas such as Transparency and Reporting, Business Ethics, Information Security and Climate Strategy. It also maintains a strong position in the 83rd percentile in areas such as Product Quality and Recall Management, Energy Management, Human Rights and global Governance. In Governance, the company stands out for a nine-point improvement compared to the previous year. This concentration in the highest percentiles reflects strong and balanced sustainability performance, clearly differentiating Grifols from its peer group.

The company’s progress compared to previous assessments has been driven by double-digit improvements in strategic areas. The most notable increases were recorded in Information Security and Product Quality and Recall Management, both rising by 26 points. Overall, these results demonstrate consistent and measurable progress in governance, operational excellence and environmental management.

The Dow Jones Best-in-Class indices include global sustainability leaders identified by S&P Global through its Corporate Sustainability Assessment. In the latest edition, 335 biotechnology companies worldwide were evaluated for their ESG performance following a rigorous comparative analysis process. Grifols’ inclusion in these indices reflects the company’s commitment to integrating responsible practices across all its operations, effectively managing ESG risks and opportunities, and contributing to a more sustainable and resilient healthcare industry.

This achievement adds to other recent recognitions that position Grifols among the top-performing companies in sustainability. Recently, the company achieved Platinum status, the highest distinction, in EcoVadis’ sustainability rating. Grifols also received Prime status in ISS ESG ratings, a BB rating in MSCI ESG Ratings, and was ranked among the top companies by Sustainalytics with a low ESG risk rating. The company also participates annually in the Carbon Disclosure Project (CDP).